India · Delayed Price · Currency is INR Happiest Minds Technologies Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 delivered strong revenue and profitability growth, driven by AI-led transformation and robust customer engagement. FY 2027 guidance targets 12.5% organic growth and higher operating margins, supported by a strong pipeline, new AI platforms, and expanded partnerships.
-
Q3 saw 2.4% sequential and 10.7% YoY revenue growth, with strong AI-led execution and margin improvement. AI First strategy is driving customer adoption, especially in BFSI and healthcare, and management remains confident in 10%+ growth, with higher guidance possible after Q4.
-
Revenue grew 11.8% in constant currency for H1 FY26, with EBITDA margin at 20.8%. Generative AI and net new sales units drove strong growth, leading to raised guidance for four years of double-digit growth. Utilization, margins, and client additions all improved.
-
Q1 FY26 saw 17.5% year-over-year growth and 21.4% EBITDA margin, with strong GenAI and BFSI performance. Double-digit growth and 20–22% EBITDA margin are targeted for FY26, supported by a robust pipeline and ongoing strategic investments.
Fiscal Year 2025
-
Achieved 25.6% constant currency revenue growth for FY 2025, driven by acquisitions and transformational initiatives. BFSI and healthcare are key growth areas, with strong GenAI momentum and a robust outlook for double-digit organic growth in FY 2026 and FY 2027.
-
Q3 saw 28.5% YoY revenue growth, strong margins, and robust deal momentum, led by BFSI and healthcare. Acquisitions and GenAI investments are driving future growth, with double-digit organic growth targeted next year.
-
Double-digit sequential and YoY revenue growth was driven by acquisitions, Gen AI investments, and strong BFSI and healthcare performance. Margins remain within guidance despite wage hikes and tech investments, with Q4 expected to be the strongest quarter.
-
Q1 FY25 saw double-digit revenue growth, strong EBITDA margins, and successful integration of two major acquisitions. The company maintained its EBITDA margin guidance and revised revenue growth forecast to 30%-35% for FY25, with continued investment in GenAI and new markets.